Spyre Therapeutics, Inc. (NASDAQ: SYRE ) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...

Factors portending the greatest risk for cardiovascular death in control patients were inflammation (baseline plasma high-sensitivity C-reactive protein =2 mg/L; p=0.003) and ischemic HFrEF etiology ...

According to new research, it appears that our efforts to keep down the cost of groceries and time spent in the kitchen have ...

The SELECTION study1 showed that the JAK 1 inhibitor filgotinib is safe and efficacious in ulcerative colitis. Based on positive results of the phase 2 FITZROY study2 in Crohn's disease, it was ...

Against the backdrop of an alarming increase in the number of people under 50 being diagnosed with bowel cancer, researchers are urging people to bump up their fiber intake and improve their eating ...